Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40622 | 1.00 | CYP1A2 (0.53) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL40623 | 1.00 | CYP1A2 (0.53) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL1269592 | 0.98 | CYP1A2 (0.52) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL1269590 | 0.98 | CYP1A2 (0.52) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| Chloromethane SCHEMBL22092026 | 0.94 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL17924705 | 0.90 | CYP1A2 (0.46) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL6046221 | 0.84 | CYP1A2 (0.42) | CYP1A2ALOX15GRM2GRM3CYP2D6 | |
| SCHEMBL24576135 | 0.80 | GRM2 (0.34) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL8289298 | 0.80 | GRM2 (0.34) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL3666260 | 0.80 | GRM2 (0.38) | CYP1A2ALOX15GRM2GRM3CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496195-A | Preparation method of (R) -4, 4-difluoro pyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116496195-A | Preparation method of (R) -4, 4-difluoro pyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496195-A | Preparation method of (R) -4, 4-difluoro pyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496195-A | Preparation method of (R) -4, 4-difluoro pyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9670183-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| EP-3102568-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015118342-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-08-13 | — | — | WO | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CYP1A2 130/4885ALOX15 952/4885GRM2 990/4885 |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CYP1A2 1435/4885ALOX15 3083/4885GRM2 4043/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP1A2 4271/4885ALOX15 3975/4885GRM2 2025/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP1A2 4052/4885ALOX15 2548/4885GRM2 3992/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP1A2 4271/4885ALOX15 3975/4885GRM2 2025/4885 |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | CYP1A2 3970/4885ALOX15 2656/4885GRM2 4183/4885 |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP1A2 483/4885ALOX15 3563/4885GRM2 81/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP1A2 483/4885ALOX15 3563/4885GRM2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.